University Of Oxford English news | University Of Oxford, Latest News & Live Updates in English | English News (Latest English News) at Lokmattimes.com

The University of Oxford, in collaboration with AstraZeneca, has announced interim trial data from its Phase III trials that show its candidate coronavirus vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator of the Oxford Vaccine Trial, said: "These findings show that we have an effective vaccine that will save many lives. Excitingly, we've found that one of our dosing regimens may be around 90% effective and if this dosing regimen is used, more people could be vaccinated with planned vaccine supply. Today's announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world."Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said: "The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by SARS-CoV-2. We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multi-national effort which will reap benefits for the whole world."Following the trial reaching the target for interim analysis, the independent Data and Safety Monitoring Board (DSMB) recommended that the team at Oxford conduct its first analysis on all the cases with data locked on 4 November 2020.These preliminary data indicate that the vaccine is 70.4% effective, with tests on two different dose regimens showing that the vaccine was 90% effective if administered at a half dose and then at a full dose, or 62% effective if administered in two full doses. Additional cases are expected to accrue by the time of the final analysis and future analyses will determine the duration of protection.Oxford will now support AstraZeneca in submitting both the interim Phase III efficacy data and the extensive safety data to all regulators across the world, including in the UK, Europe and Brazil for independent scrutiny and product approval, including for emergency use. Many of these regulators have been reviewing the trial data on a rolling basis during the trial.These data also suggest that this half dose and full dose regimen could help to prevent transmission of the virus, evidenced by lower rates of asymptomatic infection in the vaccinees, with further information to become available when trial data are next evaluated. The interim Phase III data builds on Oxford's phase I/II peer-reviewed trial results which have shown that the vaccine induces strong antibody and T cell immune responses across all age groups, including older adults, and has a good safety profile.The clinical trials, enrolling over 24,000 participants from diverse racial and geographical groups in the UK, Brazil and South Africa, will now continue to final analysis. Further trials are being conducted in the United States, Kenya, Japan and India and the trial team expect to have under 60,000 participants by the end of the year. These trials will provide regulators with further information about the efficacy and safety of the Oxford candidate vaccine, including its ability to both protect against and stop the transmission of COVID-19.The Oxford vaccine (ChAdOx1 nCoV-19) is made from a virus, which is a weakened version of a common cold virus (adenovirus), that has been genetically changed so that it is impossible for it to grow in humans.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

University Of OxfordFOLLOW

University of oxford, Latest News

There is little known research about the relationship between sleep, memory development, and literacy skills. A new study has provided initial evidence that daytime naps could be beneficial for preschool children's learning of letter-sound skills. ...

London, March 8 While brain-related abnormalities have been observed in cases of severe Covid-19, a new study suggests ... ...

A new study has shed light on the subject that does consumption of meat aggravate cancer or help in fighting it. ...

Researchers from the Nuffield Department of Population Health at the University of Oxford, the Chinese University of Hong Kong, and the University of Bristol found no evidence that a diet rich in vegetables will also lower the risk of cardiovascular ...

London, Feb 24 Severe Covid-19 in pregnancy may increase the risk of pre-labour caesarean birth, a very or ... ...

Often than not, we see ourselves gaining weight like anything, post being on even normal medication for some time. It makes us think if at all we are doing something to our bodies or is it purely the medication. But what about people with bipolar dis ...

Geneva, Feb 8 The newly-detected HIV variant from the Netherlands is more transmissible and damaging, according to research. ... ...

The University of Oxford, in collaboration with AstraZeneca, has announced interim trial data from its Phase III trials that show its candidate coronavirus vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high ...